Save Product
Product Details
Synonyms
CD47, MER6, IAP, OA3
Source
Unconjugated Human CD47, His,Avitag (CD7-HA2E9) is expressed from human 293 cells (HEK293). It contains AA Gln 19 - Pro 139 (Accession # Q08722-3).
Predicted N-terminus: Gln 19
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 16.9 kDa. The protein migrates as 33-40 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
Application
CD7-HA2E9 is the unconjugated version of CD7-H82E9 (Biotinylated Human CD47, His,Avitag). It can be utilized for assay development or customized biotinylation according to the experimental designs.
Endotoxin
Less than 1.0 EU per μg by the LAL method / rFC method.
Purity
>95% as determined by SDS-PAGE.
>90% as determined by SEC-HPLC.
Formulation
Lyophilized from 0.22 μm filtered solution in 10 mM Bicine, pH8.3 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Shipping and Storage
This product is shipped at ambient temperature.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE
Unconjugated Human CD47, His,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).
SEC-HPLC
The purity of Unconjugated Human CD47, His,Avitag (Cat. No. CD7-HA2E9) was greater than 90% as determined by SEC-HPLC.
Bioactivity-ELISA
Immobilized Human SIRP alpha, Fc Tag (Cat. No. SIA-H5251) at 2 μg/mL (100 μL/well) can bind Unconjugated Human CD47, His,Avitag (Cat. No. CD7-HA2E9) with a linear range of 2-13 ng/mL (QC tested).
Protocol
Immobilized Unconjugated Human CD47, His,Avitag (Cat. No. CD7-HA2E9) at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-Human CD47 Antibody, Human IgG4 with a linear range of 0.06-4 ng/mL (QC tested).
Protocol
Customer Reviews Writing Reviews
1***62019-10-12
LikesI used this protein to detect mouse serum titer. The product is more cost-effective, good quality, and the obtained data is highly reliable compared to RnD Systems products. In addition, when I performed other ELISA experiments, the data was greatly reproducible.
FAQ
- product
Can lyophilized proteins remain stable during room-temperature shipping or temporary room-temperature exposure?
In general, lyophilized proteins remain stable during room-temperature shipping or temporary exposure to room-temperature conditions.
Many ACROBiosystems recombinant proteins are supplied in lyophilized (freeze-dried) form. The lyophilization process effectively removes moisture from the product, helping reduce degradation-related reactions and improve protein stability during transportation and storage.
To evaluate the stability of lyophilized proteins under normal temperature conditions, ACROBiosystems conducted a stability study on 11 representative lyophilized protein products at 37°C. The study demonstrated that these proteins maintained good quality stability after storage at 37°C for approximately 20 days. Based on these validation results, temporary room-temperature exposure during shipping or handling is generally not expected to have a significant impact on product quality or downstream application performance.
To ensure optimal long-term stability, products should be stored according to the storage conditions specified in the product Certificate of Analysis (COA) upon receipt.
Supporting Document
Background
Recent Advances
Drug Development Progress- English Name：
Cluster of differentiation 47
- Category：
- Approved Drugs：
0 Details
- Drugs in Clinical Trials：
53 Details
- Highest Development Stage：
Phase 3 Clinical
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing
